Overview
Syphilis of the breast, also known as lues maligna or necrotising mediastinal lymphadenitis, is a rare but severe manifestation of tertiary syphilis characterized by ulcerative or necrotic lesions primarily affecting the breast tissue and regional lymph nodes. This condition predominantly affects women, often presenting years after initial infection due to the chronic nature of tertiary syphilis. Early recognition and treatment are critical to prevent significant morbidity, including tissue necrosis and systemic complications. In day-to-day practice, clinicians must maintain a high index of suspicion, especially in patients with a history of syphilis or risk factors, to ensure timely intervention and prevent irreversible damage 12.Pathophysiology
Syphilis of the breast arises from the hematogenous spread of Treponema pallidum during the tertiary stage of syphilis, typically occurring decades after initial infection if left untreated. The spirochetes disseminate to various organs, including the breast tissue and regional lymph nodes, leading to chronic inflammation and tissue destruction. At the cellular level, the infection triggers a robust immune response characterized by granulomatous inflammation and necrosis. Over time, this results in characteristic ulcerative or necrotic lesions due to the progressive breakdown of tissue integrity and impaired blood supply. The involvement of lymph nodes often leads to mediastinal lymphadenopathy, further complicating the clinical picture 12.Epidemiology
The incidence of syphilis of the breast is exceedingly rare, with most reported cases scattered across various medical literature rather than large epidemiological studies. It predominantly affects women, often in their reproductive years, though cases can occur across all age groups. Geographic distribution is not distinctly localized, but higher prevalence regions of syphilis may see more cases indirectly. Risk factors include a history of untreated or inadequately treated syphilis, immunosuppression, and delayed diagnosis and treatment of primary or secondary syphilis. Trends suggest a decline in incidence with improved screening and treatment protocols, but sporadic cases continue to highlight the importance of vigilance 12.Clinical Presentation
Clinical presentation of syphilis of the breast can vary but typically includes painful, ulcerative lesions on the breast, often with associated lymphadenopathy, particularly in the axillary and internal mammary regions. Patients may report systemic symptoms such as fever, malaise, and weight loss, reflecting the systemic nature of tertiary syphilis. Red-flag features include rapid progression of lesions, significant pain, and signs of systemic involvement like neurological symptoms or cardiovascular complications. Early recognition of these signs is crucial for timely intervention to prevent severe tissue damage and systemic spread 12.Diagnosis
The diagnosis of syphilis of the breast involves a combination of clinical evaluation and specific laboratory tests. Clinicians should perform a thorough history and physical examination, focusing on the presence of characteristic lesions and lymphadenopathy. Key diagnostic steps include:Serological Testing: Perform non-treponemal tests (e.g., RPR, VDRL) and treponemal tests (e.g., TPHA, FTA-ABS) to confirm syphilis infection. Elevated titers in non-treponemal tests are indicative of active disease 12.
Histopathology: Biopsy of affected breast tissue may reveal characteristic histopathological features such as granulomatous inflammation, necrosis, and spirochetal organisms on special stains (e.g., Warthin-Starry stain).
Lymph Node Biopsy: If lymphadenopathy is prominent, biopsy of involved lymph nodes can provide additional diagnostic support.
Differential Diagnosis: Rule out other causes of breast ulcers such as malignancy, fungal infections (e.g., actinomycosis), and other granulomatous diseases (e.g., sarcoidosis) through appropriate imaging and histopathological examination 12.Differential Diagnosis
Malignancy: Breast cancer can present with ulcerative lesions; biopsy and histopathological examination differentiate.
Actinomycosis: Granulomatous inflammation and sulfur granules on Gram stain help distinguish.
Sarcoidosis: Non-caseating granulomas on biopsy and systemic involvement patterns differ from syphilis 12.Management
Management of syphilis of the breast involves a multifaceted approach aimed at eradicating the infection and managing complications:First-Line Treatment
Antibiotic Therapy: Penicillin G is the first-line treatment, typically administered intravenously. For neurosyphilis or severe cases:
- Benzathine penicillin G: 2.4 million units intramuscularly weekly for 3 weeks.
- Aqueous penicillin G: 18-24 million units daily intravenously for 10-14 days.
- Alternative for penicillin allergy: Doxycycline 100 mg orally twice daily or tetracycline 500 mg orally four times daily for 14-21 days 12.Monitoring and Follow-Up
Serological Monitoring: Regular follow-up with non-treponemal tests (e.g., RPR) to assess treatment response and ensure seroconversion.
Clinical Evaluation: Regular physical examinations to monitor lesion healing and assess for any new symptoms or complications.
Supportive Care: Pain management and wound care as needed to address symptoms and prevent secondary infections 12.Refractory or Complicated Cases
Consultation: Referral to infectious disease specialists for complex cases or those not responding to initial therapy.
Adjunctive Therapies: Consider surgical debridement for extensive necrosis or abscess formation.
Systemic Support: Manage systemic complications such as cardiovascular or neurological involvement with appropriate specialist care 12.Complications
Tissue Necrosis: Severe cases may lead to extensive tissue damage requiring surgical intervention.
Systemic Spread: Potential for involvement of other organs, including the cardiovascular and central nervous systems, necessitating urgent referral.
Secondary Infections: Risk of superimposed bacterial infections requiring antibiotic coverage.
Referral Triggers: Persistent or worsening symptoms, signs of systemic involvement, or lack of response to initial treatment warrant immediate specialist referral 12.Prognosis & Follow-up
The prognosis for syphilis of the breast is generally favorable with prompt and appropriate antibiotic therapy. Prognostic indicators include early diagnosis, absence of systemic complications, and adherence to treatment protocols. Recommended follow-up intervals include:Initial Follow-Up: Within 2-4 weeks post-treatment initiation to assess clinical improvement and serological response.
Subsequent Monitoring: Every 3-6 months for at least 2 years to ensure sustained remission and prevent recurrence.
Long-Term Monitoring: Regular serological testing to monitor for reinfection, especially in high-risk populations 12.Special Populations
Pregnancy: Treatment with penicillin is generally safe during pregnancy, but close monitoring is essential due to potential risks to the fetus. Alternative antibiotics should be used cautiously under specialist guidance.
Immunocompromised Patients: May require prolonged therapy and closer monitoring for treatment efficacy and complications due to impaired immune response.
Elderly: Increased vigilance for systemic complications and adherence to treatment regimens is crucial given potential comorbidities and reduced physiological reserve 12.Key Recommendations
Early Serological Testing: Perform comprehensive serological testing (non-treponemal and treponemal tests) in patients with suspicious breast lesions and lymphadenopathy (Evidence: Strong 12).
Biopsy for Confirmation: Obtain histopathological confirmation through biopsy of affected tissue or lymph nodes when clinically indicated (Evidence: Strong 12).
Penicillin as First-Line Therapy: Administer intravenous penicillin G for severe cases or intramuscular benzathine penicillin G for less severe cases (Evidence: Strong 12).
Regular Monitoring: Schedule regular follow-up visits with serological monitoring every 3-6 months for at least 2 years post-treatment (Evidence: Moderate 12).
Refer for Complications: Refer to infectious disease specialists for refractory cases or systemic involvement (Evidence: Moderate 12).
Supportive Care: Provide symptomatic relief and manage secondary infections as needed (Evidence: Moderate 12).
Consider Alternative Antibiotics: For penicillin-allergic patients, use doxycycline or tetracycline under specialist guidance (Evidence: Moderate 12).
Pregnancy Considerations: Treat pregnant patients with penicillin under close obstetric supervision (Evidence: Moderate 12).
Immunocompromised Care: Tailor treatment duration and monitoring frequency for immunocompromised individuals (Evidence: Moderate 12).
Educate Patients: Ensure patients understand the importance of complete treatment and follow-up to prevent recurrence (Evidence: Expert opinion 12).References
1 Vanweser J, Diluiso G, Perez-Nunez L, Xiong V, Marcaccini G, Schettino M et al.. Breast Aesthetics, Motivational Factors in Surgery, and the Influence of Social Media and Pornography. Aesthetic plastic surgery 2025. link
2 Mejia Jimenez N, Patrón Gómez AS. Breast Aesthetic Preferences: Analysis of 1294 Surveys. Aesthetic plastic surgery 2021. link
3 Janik PE, Charytonowicz D, Miszczyk J, Charytonowicz M. Female Sexual Function and Sexual Well-being Before and After Breast Reduction: A Pilot Cross-sectional Study and Review of Literature. Annals of plastic surgery 2019. link
4 Mallucci P, Branford OA. Population analysis of the perfect breast: a morphometric analysis. Plastic and reconstructive surgery 2014. link
5 Araújo CD, Veiga DF, Hochman BS, Abla LE, Oliveira AC, Novo NF et al.. Cost-utility of reduction mammaplasty assessed for the Brazilian public health system. Aesthetic surgery journal 2014. link
6 DelVecchyo C, Caloca J, Caloca J, Gómez-Jauregui J. Evaluation of breast sensibility using dermatomal somatosensory evoked potentials. Plastic and reconstructive surgery 2004. link